Drugs / APS03118
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05653869 | Feb 2023 → Oct 2026 expected | RET fusion positive cancer | Applied Pharmaceutical Science, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APS03118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05653869 ↗ |
| Route | Oral | “APS03118 administered orally” NCT05653869 ↗ |